Ranbaxy’s Private-Label Loratadine OTCs Spared By FDA Probe
This article was originally published in The Tan Sheet
Executive Summary
Several first-to-file abbreviated new drug applications are on the line as Ranbaxy tries to resolve data integrity issues with FDA concerning its Paonta Sahib, India, facility
You may also be interested in...
Import Alert On Drugs From Ranbaxy’s Plants Includes OTC Product
India's largest drug maker, Ranbaxy, faces a hurdle to growing its U.S. business with FDA's ban on imports of some of its products, including an OTC drug
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.
Track-And-Trace: With Deadline a Year Away, Some Lessons from Early Adopters
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.